Health for All, Hunger for None. That’s what drives us at Bayer.

Leverkusen, Germany
Joined April 2010
NEW: A Bayer-commissioned report, with analysis by @OxfordEconomics, finds that the EU and UK risk falling further behind global agricultural competitors as climate & geopolitical pressures grow. Read the news here: spr.ly/6011BHycdN
1
5
968
Bayer plans to invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio - bringing manufacturing closer to patients and supporting the reliable production of innovative medicines at scale. Learn more: bayer.com/media/en-us/bayer-…
6
4
1
20
3,700
#NEWS: Bayer showcases its R&D pipeline at field event in Huxley, Iowa: 10 innovations each projected to reach €500M+ in peak sales, with soy trait technology alone expected to surpass €3B. Learn more: spr.ly/6018B1CEi8
8
24
4,814
Earlier today, we published our Half Year 2026 results. Our CEO, Bill Anderson, provides a 90-second overview of the progress we made last quarter and where we will put our focus for the next 90 days. Find out more: spr.ly/6013BE7fvS
12
4
25
4,621
Second quarter of 2026: @Bayer operationally on track to achieve full-year outlook, decisive progress on strategic priorities Here's our digital quarterly statement: spr.ly/6011BE7FqH
2
3
19
4,039
Earlier today, we published our Q1 2026 results. Our CEO, Bill Anderson, provides a 90-second overview of the progress we made and where we will put our focus for the next 90 days. Find out more: bayer.com/en/investors-overv…
34
1
26
4,617
Bayer has reported a solid performance across all divisions for the first quarter and confirmed its currency-adjusted outlook for 2026. Here’s our digital quarterly statement: spr.ly/6018BBt64j
20
4
9
3,156
#News: We intend to acquire Perfuse Therapeutics, a biopharmaceutical company focused on ischemia-induced ocular diseases. Acquisition complements our pharmaceutical pipeline & reinforces our commitment to developing urgently needed therapies for patients: bayer.com/media/en-us/
12
5
15
3,481
Earlier today, we published our Full Year 2025 results. Our CEO, Bill Anderson, provides a 90-second overview of the progress we made and where we will put our focus for the next 90 days. Find out more: reports.bayer.com/annual-rep…
25
6
1
34
7,025
Bayer achieved its upgraded full-year targets for 2025 and shared the company’s outlook for 2026. Here’s our digital annual report: spr.ly/6013hfo4d
6
4
17
4,971
NEW EPISODE of Long Strange Trip with Bill Anderson, CEO of @Bayer, just dropped. This episode is a master class in going Founder Mode. In 2 years he's torn down and rebuilt how a 160-year-old company operates. I hope you enjoy it. Leave a comment and let me know what struck you most.
18
10
1
53
11,472
#NEWS: Bayer presented for the first time detailed results of a pivotal Phase III study in secondary stroke prevention at the International Stroke Conference (ISC) 2026. Learn more: bayer.com/media/en-us/
9
4
17
2,985
#NEWS: The European Commission grants marketing authorization in the EU for an eye medication with long injection intervals for macular edema following retinal vein occlusion (RVO). #RVO affects 28M adults and can cause sudden vision loss.
6
2
1
6
2,901
#NEWS: The EU Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends an eye medication with extended dosing intervals for approval in the treatment of macular edema following retinal vein occlusion.
13
2
10
2,972
+++ Exciting #news ++ Bayer announces positive topline results from the international Phase III study. #TeamBayer #HealthForAll #HungerForNone
22
10
27
5,816
#News: The European Commission has approved our new hormone-free treatment option for vasomotor symptoms (VMS; also known as hot flashes) associated with menopause or caused by endocrine therapy for breast cancer.
7
3
9
3,318
Earlier today, we published our Q3 2025 results. Our CEO, Bill Anderson, provides a 90-second overview of the progress we made and where we will put our focus for the next 90 days: youtube.com/watch?v=q2pqbzNd…
7
6
1
16
2,604